Last reviewed · How we verify
Cabazitaxel (XRP6258)
Cabazitaxel is a microtubule-stabilizing taxane that binds to β-tubulin and prevents microtubule depolymerization, leading to cell cycle arrest and apoptosis in cancer cells.
Cabazitaxel is a microtubule-stabilizing taxane that binds to β-tubulin and prevents microtubule depolymerization, leading to cell cycle arrest and apoptosis in cancer cells. Used for Metastatic castration-resistant prostate cancer (mCRPC) in patients previously treated with docetaxel, Metastatic breast cancer in patients previously treated with taxanes.
At a glance
| Generic name | Cabazitaxel (XRP6258) |
|---|---|
| Also known as | Jevtana®, JEVTANA, Jevtana |
| Sponsor | Sanofi |
| Drug class | Taxane; microtubule stabilizer |
| Target | β-tubulin (microtubule) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
As a semi-synthetic taxane derivative, cabazitaxel stabilizes microtubules by binding to β-tubulin, preventing their disassembly during cell division. This causes mitotic arrest and triggers apoptosis in rapidly dividing cancer cells. Cabazitaxel has improved activity against taxane-resistant tumors compared to earlier taxanes like docetaxel and paclitaxel.
Approved indications
- Metastatic castration-resistant prostate cancer (mCRPC) in patients previously treated with docetaxel
- Metastatic breast cancer in patients previously treated with taxanes
Common side effects
- Neutropenia
- Anemia
- Leukopenia
- Diarrhea
- Fatigue
- Nausea
- Vomiting
- Peripheral neuropathy
Key clinical trials
- Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) (PHASE1, PHASE2)
- Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer (PHASE2)
- A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell Tumors (PHASE2)
- Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC) (PHASE1, PHASE2)
- A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients
- Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel (PHASE2)
- Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer (PHASE2)
- Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cabazitaxel (XRP6258) CI brief — competitive landscape report
- Cabazitaxel (XRP6258) updates RSS · CI watch RSS
- Sanofi portfolio CI